Drugs / SYN818
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07156253 | Aug 2025 → Aug 2028 expected | breast cancer, metastatic neoplasm, ovarian cancer | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06666270 | Nov 2024 → Jun 2026 overdue | breast cancer, metastatic neoplasm, ovarian cancer, prostate cancer | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06666270 ↗ |
| Action | Inhibit | “SYN818, a DNA Polymerase Theta (POLQ) Inhibitor” NCT06666270 ↗ |
| Route | Oral | “orally receive SYN818” NCT06666270 ↗ |
| Target | POLQ | “SYN818, a DNA Polymerase Theta (POLQ) Inhibitor” NCT06666270 ↗ |